REFERENCES
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
2. Miao D, Zhao J, Han Y, et al. Management of locally advanced non-small cell lung cancer: state of the art and future directions. Cancer Commun. 2024;44:23-46.
3. Corvaja C, Passaro A, Attili I, et al. Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: bridging biological insights and therapeutic development. Cancer Treat Rev. 2024;130:102824.
4. Liang SK, Wei PF, Hsieh MS, Wu CL, Shih JY. Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib. ERJ Open Res. 2024;10:00676-2023.
5. Piper Vallillo AJ, Viray H, Feldman J, Rangachari D. Management of treatment resistance in patients with advanced epidermal growth factor receptor-mutated lung cancer: personalization, parsimony, and partnership. J Clin Oncol. 2024;42:1215-21.
6. Nicoś M, Sroka-Bartnicka A, Kalinka E, Krawczyk P. Possibilities of overcoming resistance to osimertinib in NSCLC patients with mutations in the EGFR gene. Cancers. 2025;17:563.
7. Li Y, Juergens RA, Finley C, Swaminath A. Current and future treatment options in the management of stage III NSCLC. J Thorac Oncol. 2023;18:1478-91.
8. Li X, Combs JD 3rd, Salaita K, Shu X. Polarized focal adhesion kinase activity within a focal adhesion during cell migration. Nat Chem Biol. 2023;19:1458-68.
9. Hu HH, Wang SQ, Shang HL, et al. Roles and inhibitors of FAK in cancer: current advances and future directions. Front Pharmacol. 2024;15:1274209.
10. Shi Y, Ju M, Zhang Y, Liang L, Sun X, Di X. Comprehensive pan-cancer analysis of 33 human cancers reveals immunotherapeutic value of focal adhesion tyrosine kinase. Medicine. 2024;103:e37362.
11. Yang M, Xiang H, Luo G. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders. Biochem Pharmacol. 2024;224:116246.
12. Chuang HH, Zhen YY, Tsai YC, et al. FAK in cancer: from mechanisms to therapeutic strategies. Int J Mol Sci. 2022;23:1726.
13. Tozuka T, Noro R, Yoshida K, et al. Phosphoproteomic analysis identified mutual phosphorylation of FAK and Src as a mechanism of osimertinib resistance in EGFR-mutant lung cancer. JTO Clin Res Rep. 2024;5:100668.
14. Haderk F, Chou YT, Cech L, et al. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun. 2024;15:3741.
15. Kosibaty Z, Brustugun OT, Zwicky Eide IJ, et al. Ras-related protein Rab-32 and thrombospondin 1 confer resistance to the EGFR tyrosine kinase inhibitor osimertinib by activating focal adhesion kinase in non-small cell lung cancer. Cancers. 2022;14:3430.
16. Fu Y, Zhang Y, Lei Z, et al. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. J Hematol Oncol. 2020;13:169.
17. Aboubakar Nana F, Hoton D, Ambroise J, et al. Increased expression and activation of FAK in small-cell lung cancer compared to non-small-cell lung cancer. Cancers. 2019;11:1526.
18. Dy GK, Ylagan L, Pokharel S, et al. The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer. J Thorac Oncol. 2014;9:1278-84.
19. Ocak S, Chen H, Callison C, Gonzalez AL, Massion PP. Expression of focal adhesion kinase in small-cell lung carcinoma. Cancer. 2012;118:1293-301.
20. Banerjee S, Krebs MG, Greystoke A, et al. Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial. Nat Med. 2025;31:3074-80.
21. Zhu SK, Wu Q, Liu GX, Geng AQ, Wang PA. Recent advances in focal adhesion kinase (FAK)-targeting antitumor agents. RSC Adv. 2025;15:20957-84.
22. Fennell DA, Baas P, Taylor P, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-A double-blind, randomized, phase II study. J Clin Oncol. 2019;37:790-8.
23. Gerber DE, Camidge DR, Morgensztern D, et al. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer. 2020;139:60-7.
24. Pecoraro C, Carbone D, Scianò F, et al. Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: synthesis, mechanistic insights and promising antitumor and safety profile. J Drug Target. 2024;32:1278-94.
25. Sciarrillo R, Wojtuszkiewicz A, Kooi IE, et al. Using RNA-sequencing to detect novel splice variants related to drug resistance in in vitro cancer models. J Vis Exp. 2016;9:54714.
26. Bijnsdorp IV, Giovannetti E, Peters GJ. Analysis of drug interactions. In: Cree IA, editor. Cancer cell culture. Totowa: Humana Press; 2011. pp. 421-34.
27. Churchman ML, Evans K, Richmond J, et al. Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL. JCI Insight. 2016;1:86082.
28. Ichihara E, Westover D, Meador CB, et al. SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer. Cancer Res. 2017;77:2990-3000.
29. Zhou X, Zeng L, Huang Z, et al. Strategies beyond 3rd EGFR-TKI acquired resistance: opportunities and challenges. Cancer Med. 2025;14:e70921.
31. Angelopoulos PA, Passaro A, Attili I, et al. Management of MET-driven resistance to osimertinib in EGFR-mutant non-small cell lung cancer. Genes. 2025;16:772.
32. Hu D, Hu Y, Lei S, Wu D, Wang Y. MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis. BMC Cancer. 2025;25:732.
33. Wang QA, Tsai IL, Lin CY, et al. Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study. Ther Adv Med Oncol. 2025;17:17588359251321901.
34. Viray H, Piper-Vallillo AJ, Widick P, et al. A real-world study of patient characteristics and clinical outcomes in EGFR mutated lung cancer treated with first-line osimertinib: expanding the FLAURA trial results into routine clinical practice. Cancers. 2024;16:1079.
35. Groenendijk FH, Bernards R. Drug resistance to targeted therapies: déjà vu all over again. Mol Oncol. 2014;8:1067-83.
36. Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov. 2023;22:213-34.
37. Levy A, Alhazzani K, Dondapati P, et al. Focal adhesion kinase in ovarian cancer: a potential therapeutic target for platinum and taxane-resistant tumors. Curr Cancer Drug Targets. 2019;19:179-88.
38. Zhang Y, Ojalill M, Boyer A, et al. Nuclear focal adhesion kinase protects against cisplatin stress in ovarian carcinoma. Cancer Res Commun. 2024;4:3165-79.
39. Cavazzoni A, La Monica S, Alfieri R, et al. Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. Oncotarget. 2017;8:53068-83.
40. Li L, Li Z, Lu C, et al. Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling. Commun Biol. 2022;5:155.
41. Vengoji R, Macha MA, Nimmakayala RK, et al. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J Exp Clin Cancer Res. 2019;38:266.
42. Assaraf YG, Brozovic A, Gonçalves AC, et al. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat. 2019;46:100645.
43. Du Z, Kan H, Sun J, et al. Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat. 2025;82:101266.
44. Kaloni D, Diepstraten ST, Strasser A, Kelly GL. BCL-2 protein family: attractive targets for cancer therapy. Apoptosis. 2023;28:20-38.
45. Alam M, Alam S, Shamsi A, et al. Bax/Bcl-2 cascade is regulated by the EGFR pathway: therapeutic targeting of non-small cell lung cancer. Front Oncol. 2022;12:869672.
46. Vogler M, Braun Y, Smith VM, et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal Transduct Target Ther. 2025;10:91.
47. Deng J, Shimamura T, Perera S, et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res. 2007;67:11867-75.
48. Luo QY, Yang J, Di T, et al. The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer. Acta Pharmacol Sin. 2025;46:1082-96.
49. Fan X, Wu S, Wu H, et al. STAT3 mediates CAF-induced osimertinib resistance via regulating protein secretion in non-small cell lung cancer. Front Pharmacol. 2025;16:1546491.
50. Amato KR, Wang S, Tan L, et al. EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer. Cancer Res. 2016;76:305-18.
